<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/91363DD3-3DEA-4D93-93B7-7A44176DADCE"><gtr:id>91363DD3-3DEA-4D93-93B7-7A44176DADCE</gtr:id><gtr:name>Catholic University of Louvain</gtr:name><gtr:address><gtr:line1>3 Place L Pasteur</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3AF59AE5-09AD-4F68-B01A-3B8DD57A4F7E"><gtr:id>3AF59AE5-09AD-4F68-B01A-3B8DD57A4F7E</gtr:id><gtr:name>St.?Jude Medical</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/926FCE3B-DFAB-4FE7-9BF8-7372B5AA9514"><gtr:id>926FCE3B-DFAB-4FE7-9BF8-7372B5AA9514</gtr:id><gtr:name>German Cancer Research Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC"><gtr:id>AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC</gtr:id><gtr:name>Johannes Gutenberg University of Mainz</gtr:name><gtr:address><gtr:line1>University of Mainz</gtr:line1><gtr:line4>Mainz</gtr:line4><gtr:postCode>D-55099</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/91363DD3-3DEA-4D93-93B7-7A44176DADCE"><gtr:id>91363DD3-3DEA-4D93-93B7-7A44176DADCE</gtr:id><gtr:name>Catholic University of Louvain</gtr:name><gtr:address><gtr:line1>3 Place L Pasteur</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3AF59AE5-09AD-4F68-B01A-3B8DD57A4F7E"><gtr:id>3AF59AE5-09AD-4F68-B01A-3B8DD57A4F7E</gtr:id><gtr:name>St.?Jude Medical</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/926FCE3B-DFAB-4FE7-9BF8-7372B5AA9514"><gtr:id>926FCE3B-DFAB-4FE7-9BF8-7372B5AA9514</gtr:id><gtr:name>German Cancer Research Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC"><gtr:id>AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC</gtr:id><gtr:name>Johannes Gutenberg University of Mainz</gtr:name><gtr:address><gtr:line1>University of Mainz</gtr:line1><gtr:line4>Mainz</gtr:line4><gtr:postCode>D-55099</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E5AC7F34-4BD1-4120-9F04-E44157ED4C2E"><gtr:id>E5AC7F34-4BD1-4120-9F04-E44157ED4C2E</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Weber</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_13064"><gtr:id>772E715E-22B7-416A-B794-5A3E6B1C96E0</gtr:id><gtr:title>ICL Confidence in Concept 2013</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_13064</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2015-09-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>700000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>St.?Jude Medical</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Peters - ICiC2 - SJM</gtr:description><gtr:id>8DE04D28-9C83-4E52-967D-77C646D0BFE5</gtr:id><gtr:impact>None so far</gtr:impact><gtr:outcomeId>56d981f34d8f85.08082852-1</gtr:outcomeId><gtr:partnerContribution>St Jude Medical are a company (based in Boston, USA) who develop electroanatomic mapping systems for use in cardiac ablation therapy. In particular, they develop the EnSite Velocity mapping system currently used for a significant proportion of atrial catheter ablation cases at Hammersmith Hospital.

For this project they provide early access to new commercial products and technical advice on their use. They also provide exclusive or limited access to some research-related technologies. The collaboration began prior to the ICiC award but is important in Prof Peters' ICiC2 project</gtr:partnerContribution><gtr:piContribution>St. Jude Medical provide us with access to their systems and code to work with clinical data acquired for our R&amp;amp;D purposes, from which our technical insights support both our thoughts and IP, and help with their understanding the needs of clinicians in front-line cardiac arrhythmia treatment.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Engineering Glasgow</gtr:department><gtr:description>Cass - ICiC2 - PNG</gtr:description><gtr:id>1B2A0152-2846-420C-A99C-8E30CF5382BE</gtr:id><gtr:impact>The first description was submitted as an abstract for Biosensors 2016 and will be presented as a poster at the conference in May this year. The injection moulded structures are also being used in the next phase of a NIHR funded clinical studies.
Disciplines are: Chemistry, materials science, biomedical engineering</gtr:impact><gtr:outcomeId>56cdcf46599530.04893539-1</gtr:outcomeId><gtr:partnerContribution>Prof Gadegaard then used the dies to injection mould the microprobes in poly(carbonate) producing replica structures</gtr:partnerContribution><gtr:piContribution>We designed the microprobe structures and had the necessary dies machined.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Life Sciences</gtr:department><gtr:description>Snelgrove - ICiC1+2 - DrSH</gtr:description><gtr:id>5A88CA36-0207-4083-B30B-90B099360D55</gtr:id><gtr:impact>Successful generation of X-ray crystallography structures of lead compounds bound within active site of LTA4H. These will form part of a manuscript currently in preparation. They were also part of an unsuccessful application to the Wellcome Trust seeding drug discovery scheme and will form part of an application to the MRC DPFS scheme.</gtr:impact><gtr:outcomeId>56d82bf647de02.43879804-1</gtr:outcomeId><gtr:partnerContribution>Expertise in X-ray crystallography - conducted experiments and analysis.</gtr:partnerContribution><gtr:piContribution>Generation / provision of novel Leukotriene A4 hydrolase (LTA4H) modulators and recombinant LTA4H enzyme.
Knowledge of LTA4H active site and Structure-Activity Relationship (SAR) studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Catholic University of Louvain</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>Moore - ICiC2 - Early node implant trial in Belgium</gtr:description><gtr:id>DFA16BD3-3418-4DB8-A497-12E4F5F0A729</gtr:id><gtr:impact>None yet - too early</gtr:impact><gtr:outcomeId>56d03b8d936f50.89228629-1</gtr:outcomeId><gtr:partnerContribution>Operational plans for implant procedures.</gtr:partnerContribution><gtr:piContribution>All background work of implant design and manufacturing.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Heart &amp; Lung Institute (NHLI)</gtr:department><gtr:description>Snelgrove - ICiC1+2 - ProfCL</gtr:description><gtr:id>255A0B73-29A7-4C7F-8FF8-32BC55DEB698</gtr:id><gtr:impact>Successful application for an Asthma UK Innovations award. 
Studies also formed part of an unsuccessful application to the Wellcome Trust seeding drug discovery scheme and will form part of an application to the MRC DPFS scheme.
These studies are the subject of a manuscript currently being finalized.</gtr:impact><gtr:outcomeId>56d82b11b81c66.01049859-1</gtr:outcomeId><gtr:partnerContribution>Professor Lloyd is a world leader in murine models of allergic airways disease. She has provided expertise and knowledge of the models and her group have provided technical assistance.</gtr:partnerContribution><gtr:piContribution>We have utilised Professor Lloyd's models of allergic airways disease to test our LTA4H knock-out mice and LTA4H modulators. We conducted all experiments and analysis with some technical help from Professor Lloyd's group,</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johannes Gutenberg University of Mainz</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Dickinson - ICiC2 - Mainz</gtr:description><gtr:id>9D7EE63B-9EE8-45AD-BC5A-51334C0DBADE</gtr:id><gtr:impact>Crit Care Med. 2015 Jan;43(1):149-58. doi: 10.1097/CCM.0000000000000624.
Xenon improves neurologic outcome and reduces secondary injury following trauma
in an in vivo model of traumatic brain injury.

Campos-Pires R1, Armstrong SP, Sebastiani A, Luh C, Gruss M, Radyushkin K, Hirnet T, Werner C, Engelhard K, Franks NP, Thal SC, Dickinson R

BNA Meeting Edinburgh April 2015 Poster
Xenon provides short term &amp;amp; long term neuroprotection in an in vivo model of traumatic brain
Injury Rita Campos-Pires, Scott Armstrong, Anne Sebastiani, Tobi Hirnet, Clara Luh, Konstantin
Radyushkin, Serge Thal, Nicholas Franks, Robert Dickinson

Mechanisms of Anaesthesia Conference, Bonn Germany June 17th 2015: Oral presentation Rita Campos-Pires
Xenon provides short term &amp;amp; long term neuroprotection in an in vivo model of
traumatic brain</gtr:impact><gtr:outcomeId>56cdc96639b127.63479974-1</gtr:outcomeId><gtr:partnerContribution>Sharing of knowledge and techniques on brain injury models &amp;amp; neuroprotection. This collaboration was initiated prior to the ICiC award but is important to Dr Dickinson's ICiC2 project.</gtr:partnerContribution><gtr:piContribution>Sharing of knowledge and techniques on brain injury models &amp;amp; neuroprotection</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Computing</gtr:department><gtr:description>Gunn - ICiC2 - DBG &amp;amp; DJM</gtr:description><gtr:id>45406F1C-8E22-4281-8673-E68710D901DE</gtr:id><gtr:impact>An oral presentation at the IEEE Medical Imaging Conference in San Diego with associated conference proceedings to be published. This collaboration involved computer sciences with medical physics and engineering.</gtr:impact><gtr:outcomeId>56cddb2d8dbb75.10391101-1</gtr:outcomeId><gtr:partnerContribution>Dr Ben Glocker + Dr. Jiefei Ma (Department of Computing) developed the GEM software for augmented reality applications. They assisted in 3D printing phantoms used to enable successful stereo calibration of the Kinect sensors.</gtr:partnerContribution><gtr:piContribution>Prof Gunn's group including Dr Philip Noonan (Department of Medicine) implemented and evaluated GEM software modified to use multiple Kinect v2 sensors for increased field of view motion tracking in a PET/CT scanner.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Baum - ICiC2 - GlaxoSmithKline (GSK)</gtr:description><gtr:id>0AD220B0-CB27-437A-8333-B1A2CC443689</gtr:id><gtr:impact>The collaboration involves parasitology (parasite culture), biochemistry (in vitro translation) and high throughput screening. 

At present there have been no outputs to report (it is still an active collaboration). No published papers or meeting abstracts.</gtr:impact><gtr:outcomeId>56cc8ccf7a12d5.05211229-1</gtr:outcomeId><gtr:partnerContribution>GSK is providing in-house expertise and resources for the miniaturisation of our assay (once completed) towards making it industry standard for screening. This will take the form of a short term (6 weeks to 2 months) visit by Dr. Hella Baumann from the Baum lab who will work with GSK scientists to complete the miniaturisation of the assay.</gtr:partnerContribution><gtr:piContribution>Our lab is developing the in vitro drug screening assay, validating its activity and then taking this to GSK to enable miniaturisation required for high throughput drug screening of libraries.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>German Cancer Research Center</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Elson - ICiC 2 - DKFZ</gtr:description><gtr:id>18DADE6E-D1E9-45D3-84A3-9FEB144B8AA6</gtr:id><gtr:impact>Conference paper submitted to MICCAI 2017.</gtr:impact><gtr:outcomeId>58b456c67ffde5.37314681-1</gtr:outcomeId><gtr:partnerContribution>Discussion of technical ideas for processing and evaluation of structured lighting data.</gtr:partnerContribution><gtr:piContribution>Fabrication of structured lighting system with hyperspectral imaging for data acquisition in vitro and in vivo.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Bentley - ICiC 2 + 3 - ESC</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E65C4CB7-A872-4FE8-AF94-99871E69F1F0</gtr:id><gtr:impact>Presentation at conference</gtr:impact><gtr:outcomeId>56cf23e9f055c8.79665827</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://eurostroke.eu/esc-vienna-2015</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Posocco - ICiC2 - ELIMED Workshop, Italy</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B9780E95-F5F4-472A-9CF1-1EAA4C919C3E</gtr:id><gtr:impact>Piero Posocco gave a presentation at the ELIMED workshop in Catania, Italy. 

The ELIMED project aims to demonstrate the validity of new approaches based on laser- driven ion sources for potential future applications in medical and other multidisciplinary fields, including hadrontherapy. In 2018, a User-oriented beam-line, ELIMAIA (ELI Multidisciplinary Applications of laser-Ion Acceleration) equipped with diagnostics and dosimetry end-points will be commissioned at the ELI-Beamlines facility in the Czech Republic with the main goal to perform proof-of-principle experiments, dosimetry measurements and radiation biology investigations at high repetition rate. The main goal of the 3rd ELIMED workshop is to strengthen the collaboration among the international research groups involved in this challenging project and gather new ideas, proposals and additional requirements from a broad community of users coming from different fields (Physics, Biology, Medicine, Chemistry, Material Science, etc.) interested in exploiting the availability of non-conventional (laser-driven) ion beams at ELI-Beamlines.</gtr:impact><gtr:outcomeId>58c14a0d9e9532.38388790</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://agenda.infn.it/conferenceDisplay.py?confId=10978</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nowlan - ICiC2 - Imperial Festival Prototype Sensor</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2ED2D1AE-E79D-4E82-951D-D7BA7326B4B5</gtr:id><gtr:impact>A prototype of our fetal movement monitor and data from its use were displayed at the Imperial College Festival in 2015. This is the principal public outreach event for Imperial College where research projects in the college are displayed to the general public. Our display involved a prototype of the device that members of the public could handle and assess, as well as see data on its use and ask questions related to its function. Over 1000 people saw the display and the prototype. The exhibition triggered several inquiries as to the medical importance of fetal movement, and allowed the public to actually handle and even wear the monitor. Very positive feedback was received with several queries relating to the medical impact and subsequent and commercial availability of the device.</gtr:impact><gtr:outcomeId>56cc87d45c4069.26199224</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.imperial.ac.uk/be-inspired/festival/whats-on/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dickinson - ICiC2 - Imperial Festival</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8837D965-7050-4441-B3A5-F42C5D6B6027</gtr:id><gtr:impact>Research group participated in Imperial Festival (15,000 attendees, May 2016, May 2014 &amp;amp; May 2013) with Research Zone display. We participated in an event for Imperial College Alumni &amp;amp; Donors (November 2014) - see http://bit.ly/1w6K6Gi and most recently (March 2015) at in an event as part of the Imperial Fringe series that focussed on how and why scientists and doctors use animals in research see http://bit.ly/1xrwoKh.</gtr:impact><gtr:outcomeId>56cdcb36794743.90318896</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://bit.ly/1w6K6Gi</gtr:url><gtr:year>2010,2013,2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Elson - ICiC2 - Presentation at Hyperspectral Imaging &amp; Applications Conference</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C2961F88-BE37-45FD-B14F-C780A03A4C9C</gtr:id><gtr:impact>Poster presentation at conference Hyperspectral Imaging &amp;amp; Applications Conference, Ricoh Arena, Coventry</gtr:impact><gtr:outcomeId>58b451a33a6905.90854571</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Fuchter - ICiC2 - Imperial College Brain Sciences Division Away Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>87003AB8-D3DE-4553-8AF6-F6E9CD8902FD</gtr:id><gtr:impact>A research talk by Dr Fuchter at the Imperial College Brain Sciences Division Away Day on his work (medicinal chemistry) to a non-specialist, but scientific audience.</gtr:impact><gtr:outcomeId>58b00b5f580de6.37445959</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Turner - ICiC2 - ACSG</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9093D50B-C9D8-462F-998F-3932B45B0927</gtr:id><gtr:impact>15 parents of food allergic children</gtr:impact><gtr:outcomeId>56cee6dcf379e3.89007171</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.anaphylaxis.org.uk/events/support-group-map/</gtr:url><gtr:year>2012,2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Edwards, A - ICiC2 - C4 &amp; ITV</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>57C9178B-1B7B-470A-B2FF-0FAB8276CC46</gtr:id><gtr:impact>Dr Andrew Edwards gave interviews to both Channel 4 on this project for pieces timed to coincide with Jim O'Neil's report on the economic cost of AMR (14th May 2015). He is now on an expert list for both companies to provide interviews as needed in the future.</gtr:impact><gtr:outcomeId>56cefdf2ae9cc9.76602944</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dickinson - ICiC2 - Gillespie Primary School, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>19625D72-3282-4A1C-98C3-C46A6129AAD2</gtr:id><gtr:impact>Robert Dickinson is doing outreach activities with Gillespie Primary School in Highbury, north London with their innovative Lab13 Science Lab. He visited Lab13 with one of his PhD students where they talked about the brain and the body with pupils from Years 2, 4 and 6.</gtr:impact><gtr:outcomeId>58bfed1bca7c30.75592989</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Elson - ICiC2 - The Optoelectronics Global Conference 2015, Shenzhen, China</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>29B5E08E-93B8-4A5F-8DDD-2B642CEA2D96</gtr:id><gtr:impact>Annual event co-located with China International Optoelectronic Exposition in Shenzhen China. The aim of this conference is to foster interactions among broad disciplines in the optoelectronics family.</gtr:impact><gtr:outcomeId>56d02ea21fe9b5.28706763</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Moore - ICiC2 - webcast seminar for the Lymphatic  Education and Research Network</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6D04695D-FA14-4F5A-8BB8-3A53B3C3EAF9</gtr:id><gtr:impact>No public disclosures can be made until the intellectual property is protected. However, Prof. Moore made a general mention of new technologies being developed to treat oedema in a webcast seminar for the Lymphatic Education and Research Network, a charity aiming to raise awareness of this and other lymphatic disorders. Attendees from around the globe asked questions via a chat box afterward.</gtr:impact><gtr:outcomeId>56d041698cbe55.30773921</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://lymphaticnetwork.org/news-events/biomechanical-approach-lymphedema</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Elson - ICiC2 - The 4th International Conference on Biomedical Engineering and Biotechnology (ICBEB2015)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B1AE1565-EA9B-446E-B3F2-C5D5EE5560B1</gtr:id><gtr:impact>The International Conference on Biomedical Engineering and Biotechnology (ICBEB) is an international meeting held once a year. This, the fourth International Conference on Biomedical Engineering and Biotechnology (ICBEB2015) will be held in Shanghai, China, during August 18th-21st, 2015, which has been organizing after ICBEB2014, ICBEB2013, and ICBEB2012 by the ICBEB Organizing Committee.</gtr:impact><gtr:outcomeId>56d0315c46c044.92604159</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://2015.icbeb.org/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gunn - ICiC2 - PN Imperial Festival</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>622D1BA4-20EA-4E93-8660-4DB844BF4A43</gtr:id><gtr:impact>Imperial Festival showcases work performed at Imperial to the public, Friends of Imperial, and any other interested attendees. Over 12,000 people attended the festival in 2015. P. Noonan assisted B. Glocker at the Imperial Festival showcasing the head tracking and augmented reality software to over 10,000 attendees from the general public and Friends of Imperial over 3 days in May 2015.</gtr:impact><gtr:outcomeId>56cde263ad73c6.54795766</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.imperial.ac.uk/be-inspired/festival/about/festival-2015/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Edwards, A - ICiC2 - Twitter account</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FA49A982-725F-4451-8E5D-11CB8E6479C8</gtr:id><gtr:impact>Established a twitter account @bugsinblood - used this to highlight on-going work and related media interviews.</gtr:impact><gtr:outcomeId>58a5a18b5390f3.98550792</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>900000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confidence in Concept 4</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>2CFD7DC4-66E8-4585-8A53-EDD46AC11ECF</gtr:id><gtr:outcomeId>56e02fe253ee09.13733065</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confidence in Concept 3</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6F084D1A-FF72-4478-82A3-03A0652ED256</gtr:id><gtr:outcomeId>56e02fab971593.23997609</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>650810</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developmental Pathway Funding Scheme</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N027736/1</gtr:fundingRef><gtr:id>47DE22A5-0B9E-40CD-A458-E68B3AEB2C09</gtr:id><gtr:outcomeId>58bfe35ee3e724.99718821</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>226000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Improved Biomarkers &amp;amp; Clinical Outcome Measures RFA - Michael J Fox Foundation</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Michael J Fox Foundation</gtr:fundingOrg><gtr:id>4B7DBCEC-D45A-4155-865A-0779E81C9EA4</gtr:id><gtr:outcomeId>56cede5823b183.59544348</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>106564</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CASE PhD Award</gtr:description><gtr:end>2021-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N017757/1</gtr:fundingRef><gtr:id>5852CCBF-BD15-4534-A11F-094529AAB700</gtr:id><gtr:outcomeId>58bfe5d0045563.85299435</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>19010</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal Brompton &amp;amp; Harefield NHS Foundation Trust Seed Funding</gtr:description><gtr:fundingOrg>Royal Brompton &amp; Harefield NHS Foundation Trust</gtr:fundingOrg><gtr:id>89DEB8DB-D1CC-4C0F-947B-ABBF57F3782F</gtr:id><gtr:outcomeId>56e039d7bd9cc9.11544359</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>55000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UK-India Educational Research Initiative</gtr:description><gtr:end>2020-04-02</gtr:end><gtr:fundingOrg>British Council</gtr:fundingOrg><gtr:id>AC79029F-2FC1-4B6B-B4B8-69D09B5D73B0</gtr:id><gtr:outcomeId>58a31d4df14371.31070082</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>108000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Pathfinder Award</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>61423CCF-F4A9-491E-9EE0-73BF7F4439B9</gtr:id><gtr:outcomeId>56cc8e052b6187.02357718</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>296000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Project Grant</gtr:description><gtr:end>2018-11-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>6ADD7893-9D33-4C01-A0C4-10A15A0217A3</gtr:id><gtr:outcomeId>56d998803658d8.49138261</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Enhancement Grant</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>F0CA00DC-8284-4E64-8AA0-A93D520604FC</gtr:id><gtr:outcomeId>56cc345ca1b8c7.81184234</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Imperial Innovations Proof of Concept Grant</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>Imperial Innovations</gtr:fundingOrg><gtr:id>0371460B-13DA-472C-BDC3-89313A4412C6</gtr:id><gtr:outcomeId>56d0625b943757.27340826</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>125000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pathfinder</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>204337/Z/16/Z</gtr:fundingRef><gtr:id>4E931D48-D15C-4233-806E-E6640D8DF66A</gtr:id><gtr:outcomeId>58a59cb3b31db1.81645346</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Heart &amp; Lung Institute (NHLI)</gtr:department><gtr:description>NHLI Independent Research Fellowship</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Imperial College London</gtr:fundingOrg><gtr:id>5C3E157B-C08E-4159-8D19-C142252F6764</gtr:id><gtr:outcomeId>56d997f0bc4f45.64692475</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>18392</gtr:amountPounds><gtr:country>Korea, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Basic Research Capability Enhancement Program</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>National Research Foundation of Korea</gtr:fundingOrg><gtr:id>1469649E-3BFE-46AD-B48F-B6C1056C92F5</gtr:id><gtr:outcomeId>56cb27ee35f276.14208092</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>286000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DPFS</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M025004/1</gtr:fundingRef><gtr:id>3E379266-A92A-4D2A-9830-1F521999ED35</gtr:id><gtr:outcomeId>56cddd2eb2ec21.13718659</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Lymphoedema is generally considered to be incurable, and in the UK occurs most often in post-surgical breast cancer patients. The standard of care to prevent metastases is to remove lymph nodes, which unfortunately also removes the principal lymph drainage pathway for the arm. It is estimated that up to &amp;frac12; of 42,000 patients who receive these procedures in the UK will develop lymphoedema. Our patented implantable device aims to replace the fluid delivery role of native lymph nodes by imitating their fluid flow characteristics. Long-term goals include a series of additional design features that facilitate restoration and enhancement of immune function to enhance diagnosis and treatment of various cancers.</gtr:description><gtr:grantRef>MC_PC_13064</gtr:grantRef><gtr:id>06A8EA2A-EBCC-4EB2-97E2-EF07B0C3EBF5</gtr:id><gtr:impact>N/A</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58ca687910b163.09967730</gtr:outcomeId><gtr:patentId>WO 2016/083784 A1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Lymph node replacement construct</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Turner - ICiC2 - Joint Committee on Vaccination and Immunisation (JCVI)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>BEB89703-8643-4C0F-9A63-D5B43D89B8A3</gtr:id><gtr:impact>Asked to advise the Joint Committee on Vaccination and Immunisation (JCVI) which advises UK health departments on immunisation relating to
influenza.</gtr:impact><gtr:outcomeId>56cee910b99f65.39518808</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type><gtr:url>https://www.gov.uk/government/publications/influenza-the-green-book-chapter-19</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>The system consists of a modified Microsoft Kinect v2 which is rigidly mounted inside the scanner bore of a PET/CT scanner. Software tracks the position of the subject's head using the 3D data provided by the Kinect v2. Currently we are acquiring 40 research PET/CT clinical brain scans with motion data to perform motion correction in the aim of reducing image blur. This is funded using a Medical Research Council Development Pathway Funding Scheme.</gtr:description><gtr:id>DBC7FF42-741E-4AE8-A093-45442B13DF1B</gtr:id><gtr:impact>The software and techniques developed could be applied to other aspects of healthcare such as respiratory monitoring.</gtr:impact><gtr:outcomeId>56cddf0c454814.36623763</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Gunn - ICiC2 - Prototype Kinect v2 near mode sensor</gtr:title><gtr:type>Support Tool - For Fundamental Research</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>We are testing it for efficacy in small numbers of patients</gtr:description><gtr:id>9DA20F98-9266-421E-8EDA-94CD049DA19F</gtr:id><gtr:impact>Won NHS Innovation Prize and UK Stroke Forum Patients Carers and Public Involvement Prize</gtr:impact><gtr:outcomeId>56d02734f3a7e5.46542143</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Bentley - ICiC2 - gripAble</gtr:title><gtr:type>Therapeutic Intervention - Medical Devices</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed a cell free protein translation assay and optimised this to 384 well plate (and validated it) to screen for potential drugs that inhibit protein translation. The assay was validated with both known and unknown drugs. The assay is based on 384 well plate and use of a spectrofluorometer, detecting luminescence from a luciferase-derived protein, expression by a parasite cell free lysate.</gtr:description><gtr:id>E3B31F1B-F753-4BC9-914D-3075689813D4</gtr:id><gtr:impact>We are hoping this tool will enable us to source funding to undertake high throughput screening of novel antimalarials in collaboration with the University of Dundee.</gtr:impact><gtr:outcomeId>58b597681859e4.73746397</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Baum - ICiC2 - Method for high throughput screening for potential inhibitors of malaria parasite (Plasmodium falciparum) protein translation in vitro</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Gold/silver nanostars are excellent structures for performing surfaced enhanced Raman spectroscopy (SERS). The method involves coating polymer microprobe structures, originally designed for minimally invasive continuous glucose sensing, with the nanostars and using these for minimally invasive sensing of other metabolites in the interstitial fluid by SERS. For additional specificity and sensitivity the nanostars can be modified with aptamers</gtr:description><gtr:id>7606C56A-8E2B-4882-BF6B-F4FCAF86E1D5</gtr:id><gtr:impact>This tool is still being developed and has not yet generated any published or otherwise reported impacts.</gtr:impact><gtr:outcomeId>56cdd03b858858.27716207</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Cass - ICiC2 - Nanostars</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Matlab code developed to analyse electroanatomic mapping data from patients in atrial fibrillation undergoing cardiac ablation. It computes the phase of the signal to identify activations of significantly varying amplitude, windows the signal and computes wavefront trajectories across the mapping area so as to identify the nature of propagation and direction of originating source.</gtr:description><gtr:id>6DF48B9D-76F6-43AC-9862-A1967E1127D7</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>56d7271c1f23e8.89201548</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Peters - ICiC2 - AFWT</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The program aimed to develop a drug screening assay based on a method of processing parasite lysate into an in vitro competent expression system that can then be used in a plate based (high throughput) screening assay, monitoring for fluorescence/luminescence.</gtr:description><gtr:id>6DAA5123-37CA-4DA1-AAFD-30335A0B2F93</gtr:id><gtr:impact>Once developed the assay platform will provide a means to screen libraries of drugs for potential antimalarials that target protein translation.</gtr:impact><gtr:outcomeId>56cd7f110faa10.54621175</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Baum - ICiC2 - Translation-Inhibition</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9587E47C-24EB-45F4-93E5-C91D31B639AA</gtr:id><gtr:title>Direct Targeting of the Ras GTPase Superfamily Through Structure- Based Design</gtr:title><gtr:parentPublicationTitle>Current Topics in Medicinal Chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b8a145aea68b374f38f6438a9e8e948"><gtr:id>3b8a145aea68b374f38f6438a9e8e948</gtr:id><gtr:otherNames>Zhao W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>5a6f087e423026.07842797</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E33603B-D953-48F0-A5CB-4B5B12D1726C</gtr:id><gtr:title>Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure.</gtr:title><gtr:parentPublicationTitle>EBioMedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e70bb9c224759fd46db8753ad9d366c2"><gtr:id>e70bb9c224759fd46db8753ad9d366c2</gtr:id><gtr:otherNames>Pitcher DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2352-3964</gtr:issn><gtr:outcomeId>5675ea7aebefc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1584D20A-5931-454D-90D9-8ECDF3BEEB00</gtr:id><gtr:title>Matrikines are key regulators in modulating the amplitude of lung inflammation in acute pulmonary infection.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d430dce3435ed73209ba8ffeb58ced44"><gtr:id>d430dce3435ed73209ba8ffeb58ced44</gtr:id><gtr:otherNames>Akthar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5aa132b4ba6ea0.08196953</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D918329-41A0-41CD-A655-39701DFEDE2F</gtr:id><gtr:title>Repurposing the Microsoft Kinect for Windows v2 for external head motion tracking for brain PET.</gtr:title><gtr:parentPublicationTitle>Physics in medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ef89c2d206e280c539a6bcfb55c7c84"><gtr:id>9ef89c2d206e280c539a6bcfb55c7c84</gtr:id><gtr:otherNames>Noonan PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0031-9155</gtr:issn><gtr:outcomeId>56cdd9b8898f65.61167939</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21C4F924-EFA8-45BD-BCF7-DFC6F6CBB18A</gtr:id><gtr:title>Evaluation of a minimally invasive glucose biosensor for continuous tissue monitoring.</gtr:title><gtr:parentPublicationTitle>Analytical and bioanalytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8616d2352dbea8b78e93784790b11c4"><gtr:id>c8616d2352dbea8b78e93784790b11c4</gtr:id><gtr:otherNames>Sharma S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1618-2642</gtr:issn><gtr:outcomeId>585d589ee9f1b1.88217784</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1BBF71B-73D6-4A22-B297-9A2C6B8EDC4C</gtr:id><gtr:title>Bionanotechnology. Colloidal nanoparticles as advanced biological sensors.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45fece0ea7c43a747b86e4ad23e3c8a8"><gtr:id>45fece0ea7c43a747b86e4ad23e3c8a8</gtr:id><gtr:otherNames>Howes PD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>56cb2245c90454.66006325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>237C86B1-0812-4964-9E23-DC74786EF58C</gtr:id><gtr:title>Direct Targeting of the Ras GTPase Superfamily Through Structure- Based Design.</gtr:title><gtr:parentPublicationTitle>Current topics in medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b8a145aea68b374f38f6438a9e8e948"><gtr:id>3b8a145aea68b374f38f6438a9e8e948</gtr:id><gtr:otherNames>Zhao W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1568-0266</gtr:issn><gtr:outcomeId>585d655ddb7b61.57003720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67D5909B-6807-4789-9D78-771CB2D26721</gtr:id><gtr:title>Argon: A Noble Foe for Subarachnoid Hemorrhage.</gtr:title><gtr:parentPublicationTitle>Critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a7a5614ed04ebd68afbd6d48c2a46d1"><gtr:id>4a7a5614ed04ebd68afbd6d48c2a46d1</gtr:id><gtr:otherNames>Campos-Pires R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0090-3493</gtr:issn><gtr:outcomeId>585d5da0902db6.16957163</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B370C2A4-06EA-4EF3-8C11-6DFFDA58972D</gtr:id><gtr:title>Phospholipase A2 as a point of care alternative to serum amylase and pancreatic lipase.</gtr:title><gtr:parentPublicationTitle>Nanoscale</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/966fe7ee62c749bddfb3ff345f886d51"><gtr:id>966fe7ee62c749bddfb3ff345f886d51</gtr:id><gtr:otherNames>Liu NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2040-3364</gtr:issn><gtr:outcomeId>58b81691c9db76.34149952</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DB712FC-0B35-4DDC-BF85-3CFE28674C24</gtr:id><gtr:title>Thienopyrimidinone Based Sirtuin-2 (SIRT2)-Selective Inhibitors Bind in the Ligand Induced Selectivity Pocket.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d452421f99a2115800ffcf32d2b0a627"><gtr:id>d452421f99a2115800ffcf32d2b0a627</gtr:id><gtr:otherNames>Sundriyal S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>58aadb83426e86.25933446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAF318D8-8AD8-40B1-B86A-397914C47B23</gtr:id><gtr:title>An endoscopic structured light system using multispectral detection.</gtr:title><gtr:parentPublicationTitle>International journal of computer assisted radiology and surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1d5d0a91b96e9fce23128b9e1577b10"><gtr:id>c1d5d0a91b96e9fce23128b9e1577b10</gtr:id><gtr:otherNames>Lin J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1861-6410</gtr:issn><gtr:outcomeId>56d02af8c1c6e3.98409230</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E96B4808-81C9-45C0-8500-D48A1AF5DB17</gtr:id><gtr:title>N-Myristoyltransferase Inhibition Induces ER-Stress, Cell Cycle Arrest, and Apoptosis in Cancer Cells.</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/793e5a3fdbbbfc8d5c6eb2675c2677cf"><gtr:id>793e5a3fdbbbfc8d5c6eb2675c2677cf</gtr:id><gtr:otherNames>Thinon E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn><gtr:outcomeId>58aebfd3014f31.38855087</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>436E4550-1605-4BA0-8F49-B3DE65CC888D</gtr:id><gtr:title>Rapid, low cost prototyping of transdermal devices for personal healthcare monitoring.</gtr:title><gtr:parentPublicationTitle>Sensing and Bio-Sensing Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8616d2352dbea8b78e93784790b11c4"><gtr:id>c8616d2352dbea8b78e93784790b11c4</gtr:id><gtr:otherNames>Sharma S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2214-1804</gtr:issn><gtr:outcomeId>585d69052cb063.18392982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00972CCF-08E2-440C-A6D8-C531FC06612E</gtr:id><gtr:title>Intranasal live-attenuated influenza vaccine (LAIV) is unlikely to cause egg-mediated allergic reactions in egg-allergic children.</gtr:title><gtr:parentPublicationTitle>The journal of allergy and clinical immunology. In practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4f783d23f29317f12815b5467a91d4b"><gtr:id>c4f783d23f29317f12815b5467a91d4b</gtr:id><gtr:otherNames>Turner PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56cde6ca5adb06.30964849</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6876FBDE-E076-4DAB-9C83-99735D89B017</gtr:id><gtr:title>Xenon improves neurologic outcome and reduces secondary injury following trauma in an in vivo model of traumatic brain injury.</gtr:title><gtr:parentPublicationTitle>Critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a7a5614ed04ebd68afbd6d48c2a46d1"><gtr:id>4a7a5614ed04ebd68afbd6d48c2a46d1</gtr:id><gtr:otherNames>Campos-Pires R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0090-3493</gtr:issn><gtr:outcomeId>5675dbbc1763c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E47A4AF-8D04-45B3-BEC0-287C27CAB9C6</gtr:id><gtr:title>The development of novel LTAH modulators to selectively target LTBgeneration.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c0a6b756c854d2c38bb292a7f93075c"><gtr:id>3c0a6b756c854d2c38bb292a7f93075c</gtr:id><gtr:otherNames>Low CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa13277e26560.36247186</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D02E3903-F3DD-4AA4-A401-078E45106F1B</gtr:id><gtr:title>Xenon Protects against Blast-Induced Traumatic Brain Injury in an In Vitro Model.</gtr:title><gtr:parentPublicationTitle>Journal of neurotrauma</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a7a5614ed04ebd68afbd6d48c2a46d1"><gtr:id>4a7a5614ed04ebd68afbd6d48c2a46d1</gtr:id><gtr:otherNames>Campos-Pires R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0897-7151</gtr:issn><gtr:outcomeId>5a6f053476d1d1.38242217</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_13064</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>